Male impotence

Lancet

Volumn 354, Issue 9191, 1999, Pages 1713-1718

  Morgentaler, Abraham ^a  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APOMORPHINE; PAPAVERINE; PHENTOLAMINE; PROSTAGLANDIN E1; SILDENAFIL; TESTOSTERONE;

CLINICAL TRIAL; DYSPEPSIA; ERECTILE DYSFUNCTION; FIBROSIS; FLUSHING; HEADACHE; HUMAN; MALE; ORAL DRUG ADMINISTRATION; PATIENT SATISFACTION; PENIS PROSTHESIS; PHASE 3 CLINICAL TRIAL; PHYSICAL EXAMINATION; PRIAPISM; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW;

EID: 0033552426     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(99)06586-1     Document Type: Review

References (30)

1. NIH Consensus Development Panel on Impotence. JAMA 1998; 270: 83-90.
2. Feldman H.A., Goldstein I., Hatzichristou D.G., Krane R.J., McKinlay J.B. Impotence and its medical and psychosocial correlates: results of the Massachusetts male aging study. J Urol. 151:1994;54-61.
3. Morley J.E. Impotence in older men. Hosp Practice. 23:1988;139-142.
4. Laumann E.O., Paik A., Rosen R.C. Sexual dysfunction in the United States: prevalence and predictors. JAMA. 281:1999;537-544.
5. Masters, W.H., Johnson, V.E. Human sexual inadequacy. Little, Brown, and Company: Boston, 1990.
6. Virag R. Intracavernous injection of papaverine for erectile failure. Lancet. ii:1982;938.
7. Rajfer J., Aronson W.J., Bush P.A., Dorey F.J., Ignarro L.J. Nitric oxide as a mediator of relaxation of the corpora cavernosum in response to nonadrenergic, noncholinergic neurotransmission. N Engl J Med. 326:1992;90-94.
8. Wespes E., Sattar A.A., Golzarian J., Wery D., Daoud N., Schulman C.C. Corporeal veno-occlusive dysfunction: predominantly intracavernous muscular pathology. J Urol. 157:1997;1678-1680.
9. Penson D.F., Ng C., Cai L., Rajfer J., Gonzalez-Cavidad N.F. Androgen and pituitary control of penile nitric oxide synthase and erectile function in the rat. Biol Reprod. 55:1996;567-574.
10. Morley J.E., Korenman S.G., Kaiser F.E., Mooradian A.D., Viosca S.P. Relationship of penile brachial pressure index to myocardial infarction and cerebrovascular accidents in older men. Am J Med. 84:1988;445-448.
11. Morgentaler A., Bruning C.O. Iatrogenic male sexual dysfunction. American Urological Association Update Series. 15:1996;70-76.
12. Karacan I. Clinical value of nocturnal erection in the prognosis and diagnosis of impotence. Med Aspects Hum Sex. 4:1970;227-234.
13. Montorsi F., Bergamaschi F., Guazzoni G., Ferini-Strambi L., Rigatti P. Morphodynamic assessment of penile circulation in impotent patients: the role of duplex and color Doppler sonography. Scand J Urol Nephrol. 27:1993;399-408.
14. Goldstein I., Lue T.F., Padma-Nathan H., Rosen R.C., Steers W.D., Wicker P.A. Oral sildenafil in the treatment of erectile dysfunction. N Engl J Med. 338:1998;1397-1404.
15. Rendell M.S., Rajfer J., Wicker P.A., Smith M.D. Sildenafil for treatment of erectile dysfunction in men with diabetes: a randomized controlled trial. JAMA. 281:1999;421-426.
16. Derry F.A., Dinsmore W.W., Fraser M.et al. Efficacy and safety of oral sildenafil (Viagra) in men with erectile dysfunction caused by spinal cord injury. Neurology. 51:1998;1629-1633.
17. Zippe C.D., Kedia A.W., Kedia K., Nelson D.R., Agarwal A. Treatment of erectile dysfunction after radical prostatectomy with sildenafil citrate (Viagra). Urology. 52:1998;963-966.
18. Ballard S.A., Gingell C.J., Tang K., Turner L.A., Price M.E., Naylor AM. Effects of sildenafil on the relaxation of human corpus cavernosum tissue in vitro and on the activities of cyclic nucleotide phosphodiesterase isozyme. J Urol. 159:1998;2164-2171.
19. Cheitlin M.D., Hutter A.M., Brindis R.G.et al. Use of sildenafil (Viagra) in patients with cardiovascular disease. ACC/AHA expert consensus document. J Am Coll Cardiol. 33:1999;273-282.
20. Morales A., Condra M., Owen J.A., Fenemore J., Surridge D.H. Oral transcutaneous pharmacologic agents in the treatment of impotence. Urol Clin N Am. 15:1988;87-93.
21. Schramek P., Dorninger R., Waldhauser M., Koneeny P., Porpaczy P. Prostaglandin E1 in erectile dysfunction: efficiency and incidence of priapism. Br J Urol. 65:1990;68-71.
22. Gupta R., Kirschen J., Barrow R.C., Eid J.F. Predictors of success and risk factors for attrition in the use of intracavernous injection. J Urol. 157:1997;1681-1686.
23. Porst H. Transurethral alprostadil with MUSE (medication urethral system for erection vs intracavernous alprostadil - a comparative study in 103 patients with erectile dysfunction. Int J Impotence Res. 9:1997;187-192.
24. Jarow J.P., Nana-Sinkam P., Sabbagh M., Eskew A. Outcome analysis of goal directed therapy for impotence. J Urol. 155:1996;1609-1612.
25. Khoudary K., DeWolf W.C., Bruning C.O., Morgentaler A. Immediate sexual rehabilitation in radical prostatectomy patients by simultaneous placement of penile prosthesis: initial results in 50 patients. Urology. 50:1997;395-399.
26. Sohn M.H.H. Current status of penile revascularization for the treatment of male erectile dysfunction. J Androl. 15:1994;183-186.
27. Morgentaler A., Bruning C.O., DeWolf W.C. Incidence of occult prostate cancer among men with low total or free serum testosterone. JAMA. 276:1996;1904-1906.
28. Becker A.J., Stief C.G., Machtens S.et al. Oral phentolamine as treatment for erectile dysfunction. J Urol. 159:1998;1214-1216.
29. Heaton J.P., Morales A., Adams M.A., Johnston B., el-Rashidy R. Recovery of erectile dysfunction by the oral administration of apomorphine. Urology. 45:1995;200-206.
30. Berman J., Berman L., Goldstein I. Female sexual dysfunction: past, present, and future. Med Aspects Hum Sex. 1:1998;15-20.